Product Overview

Glimepiride 1 mg (Generic) is an oral antidiabetic agent indicated for the management of type 2 diabetes mellitus. Manufactured by Sun Pharmaceutical Industries Ltd, this medication is supplied in a convenient strip containing ten tablets, each delivering a precise 1 mg dose of glimepiride. The product is available in pack sizes of 60, 90, and 120 tablets, allowing patients and caregivers to select the most appropriate supply for ongoing therapy. Shipping times range from six to fifteen days, depending on the destination and fulfillment center.

What is Glimepiride 1 mg (Generic)

Glimepiride belongs to the sulfonylurea class of drugs, which lower blood glucose by stimulating pancreatic beta‑cells to release insulin. The generic formulation contains the same active ingredient as the branded version, meeting the regulatory standards set by the U.S. Food and Drug Administration (FDA) for strength, purity, and dosage uniformity. Each tablet is film‑coated to protect the drug from gastric degradation and to ensure consistent absorption.

Uses and Benefits

The primary indication for glimepiride 1 mg is as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Clinical studies have demonstrated that regular use of glimepiride can reduce fasting plasma glucose and hemoglobin A1c levels, key markers of long‑term diabetic management. Benefits include:

• Effective reduction of post‑prandial and basal glucose concentrations
• Convenient once‑daily dosing that supports adherence
• Compatibility with other oral hypoglycemics or insulin when needed
• Cost‑effective option due to generic status

These advantages make glimepiride a valuable component of comprehensive diabetes care plans.

How It Works

Glimepiride exerts its hypoglycemic effect by binding to the sulfonylurea receptor (SUR1) on the surface of pancreatic beta‑cells. This interaction triggers closure of ATP‑sensitive potassium channels, leading to membrane depolarization and subsequent calcium influx. The resulting rise in intracellular calcium promotes insulin secretion in a glucose‑dependent manner. Because insulin release is modulated by ambient glucose levels, the risk of hypoglycemia is primarily linked to dosing and patient-specific factors rather than the drug’s mechanism alone.

Dosage Guidelines

Initial therapy typically begins with a single 1 mg tablet taken orally once daily, preferably with breakfast or the first main meal of the day. The dosage may be titrated upward in increments of 1 mg at intervals of 1–2 weeks, based on individual glycemic response and tolerability, up to a maximum recommended daily dose of 8 mg (often administered as 4 mg twice daily). Dose adjustments are essential for patients with renal impairment, elderly individuals, or those with hepatic dysfunction. It is advisable to monitor blood glucose frequently during dose escalation to avoid excessive hypoglycemia.

Side Effects

Like all medications, glimepiride can be associated with adverse effects. The most commonly reported side effects include:

• Hypoglycemia, especially when combined with other glucose‑lowering agents
• Weight gain, reflecting increased insulin‑mediated glucose uptake
• Gastrointestinal discomfort such as nausea or abdominal pain
• Dermatologic reactions including rash or pruritus

Serious but less frequent events may involve hepatic enzyme elevations or hypersensitivity reactions. Patients should discontinue the medication and seek medical attention if they experience signs of severe hypoglycemia (e.g., confusion, seizures) or an allergic response.

Warnings and Precautions

Prior to initiating glimepiride therapy, healthcare providers should assess:

• Renal function; dose reduction is recommended when the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73 m².
• Concurrent medications that may potentiate hypoglycemia, such as other sulfonylureas, insulin, or certain beta‑blockers.
• Pregnancy and lactation; glimepiride is generally not recommended during pregnancy due to potential fetal exposure.

Patients should be instructed to maintain regular meals and to carry a source of glucose (e.g., glucose tablets or a carbohydrate snack) in case of hypoglycemic episodes. Routine laboratory monitoring of liver enzymes, kidney function, and glycemic control is advised at intervals determined by the prescribing clinician.

Frequently Asked Questions

1. What is the typical starting dose of glimepiride 1 mg?

The usual starting dose is one 1 mg tablet taken once daily with the first main meal of the day. Dose titration is based on blood glucose response and should not exceed the maximum recommended daily dose without medical supervision.

2. Can glimepiride be used in patients with type 1 diabetes?

No. Glimepiride is indicated only for type 2 diabetes mellitus. Its use in type 1 diabetes is not recommended because the underlying pathophysiology differs and the drug may increase the risk of ketoacidosis.

3. How does glimepiride differ from metformin?

Glimepiride belongs to the sulfonylurea class and works by stimulating insulin secretion, whereas metformin primarily reduces hepatic glucose production and improves insulin sensitivity. They are often used together in combination therapy, but they have distinct mechanisms and side‑effect profiles.

4. Is it safe to drink alcohol while taking glimepiride?

Alcohol consumption can potentiate the hypoglycemic effect of glimepiride and increase the risk of severe hypoglycemia, especially when alcohol is consumed on an empty stomach. Patients should limit alcohol intake and monitor glucose levels closely.

5. What should I do if I miss a dose?

If a dose is missed, the patient should take it as soon as remembered, provided it is not close to the time of the next scheduled dose. In such cases, it is advisable to skip the missed dose and resume the regular dosing schedule rather than double up.

For additional clinical guidance, refer to reputable sources such as the National Center for Biotechnology Information, the U.S. Food and Drug Administration, or MedlinePlus.

Related Products

• Famotidine 20mg (Generic)
• Omesec 20 mg (Omeprazole)
• Pantocid DSR (Pantoprazole/Domperidone)
• Famotidine 40mg (Generic)
• Famocid 20mg (Famotidine)
• Famocid 40mg (Famotidine)
• Famocid (Famotidine)
• Supatret 0.04% Gel (Tretinoin)
• Supatret 0.1% Gel (Tretinoin)
• Supatret C Gel (Clindamycin/Tretinoin)
• Supatret Gel (Tretinoin)
• Acitretin 25mg (Generic)